NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $494,000 | -$13M |
| 2025 Q4 | 0.00 | $672,000 | -$15M |
| 2025 Q3 | -0.02 | $200,000 | -$13M |
| 2025 Q2 | -0.01 | $131,000 | -$7M |
| 2025 Q1 | -0.01 | $375,000 | -$9M |
| 2024 Q4 | -0.02 | $231,000 | -$20M |
| 2024 Q3 | -0.02 | $357,000 | -$8M |
| 2024 Q2 | -0.02 | $510,000 | -$17M |